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Airway epithelial NF-κB activation is observed in asthmatic subjects and is a cause of airway
inflammation in mouse models of allergic asthma. Combination therapy with inhaled short-
acting β2-agonists and corticosteroids significantly improves lung function and reduces
inflammation in asthmatic subjects. Corticosteroids operate through a number of mech-
anisms to potently inhibit NF-κB activity. Since β2-agonists can induce expression of
11β-HSD1, which converts inactive 11-keto corticosteroids into active 11-hydroxy corticos-
teroids, thereby potentiating the effects of endogenous glucocorticoids, we examined
whether this mechanism is involved in the inhibition of NF-κB activation induced by the
β-agonist albuterol in airway epithelial cells. Treatment of transformed murine Club cells
(MTCC) with (R)-albuterol (levalbuterol), but not with (S)- or a mixture of (R+S)- (racemic)
albuterol, augmented mRNA expression of 11β-HSD1. MTCC were stably transfected with
luciferase (luc) reporter constructs under transcriptional regulation by NF-κB (NF-κB/luc)
or glucocorticoid response element (GRE/luc) consensus motifs. Stimulation of NF-κB/luc
MTCC with lipopolysaccharide (LPS) or tumor necrosis factor-α (TNFα) induced luc activity,
which was inhibited by pretreatment with (R)-, but not (S)- or racemic albuterol. Further-
more, pretreatment of GRE/luc MTCC with (R)-, but not with (S)- or racemic albuterol,
augmented 11-keto corticosteroid (cortisone) induced luc activity, which was diminished
by the 11β-HSD inhibitor glycyrrhetinic acid (18β-GA), indicating that there was a conversion
of inactive 11-keto to active 11-hydroxy corticosteroids. LPS- and TNFα-induced NF-κB/luc
activity was diminished in MTCC cells treated with a combination of cortisone and (R)-
albuterol, an effect that was inhibited by 18β-GA. Finally, pretreatment of MTCC cells
with the combination of cortisone and (R)-albuterol diminished LPS- and TNFα-induced
pro-inflammatory cytokine production to an extent similar to that of dexamethasone.
These results demonstrate that levalbuterol augments expression of 11β-HSD1 in airway
epithelial cells, reducing LPS-induced NF-κB transcriptional activity and pro-inflammatory
cytokine production through the conversion of inactive 11-keto corticosteroids into the
active 11-hydroxy form in this cell type.
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INTRODUCTION
Asthma affects over 300 million Americans, causing morbidity
and mortality through an inability to breathe effectively (1). The
pathogenesis of asthma is characterized by airway inflammation,
airflow obstruction, and bronchial hyperresponsiveness (2). A
classic anti-inflammatory medication used in the treatment of
asthma and in animal models of the disease is corticosteorids
such as the endogenous human glucocorticoid, hydrocortisone,
and synthetic glucocorticoids, including prednisone, budesonide,
fluticasone, and dexamethasone (3), the latter of which have
greater and protracted activity profiles compared to the endoge-
nous molecules. This comes with a cost; long-term and high-dose
glucocorticoid treatment can have serious side-effects, includ-
ing a general feeling of malaise (e.g., weight gain and bloating),
immunosuppression, cataracts, dysphonia, growth retardation in
children, and osteoporosis in adults (4).
Glucocorticoids inhibit inflammation through multiple mech-
anisms (5), an important one involving interference with NF-κB,
a pleiotropic transcription factor that is activated in response to
inflammatory cytokines, mitogens, physical and oxidative stress,
infection and microbial products, as well as allergens (6). NF-κB
regulates a number of responses in mammalian cells, including the
expression of many pro-inflammatory cytokines and chemokines
(7, 8). NF-κB is active in the airway epithelium of both asth-
matic patients (9–12) and in mouse models of the disease (13),
wherein it is a signal critical in evoking pulmonary inflammation
(8). We have demonstrated that inhibition of NF-κB activity in
the airway epithelium of mice is sufficient to diminish many of
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the inflammatory features of both an ovalbumin (14) and a house
dust mite (15) model of asthma, while activation of airway epithe-
lial NF-κB exacerbates allergic airway disease (16) and enables
allergic sensitization to an innocuous inhaled antigen (17).
The tissue levels of bioactive glucocorticoids are modulated by
11β-hydroxysteroid dehydrogenases (11β-HSD), which intercon-
vert corticosteroids between inactive and active states (18); only
the active forms of corticosteroids are capable of interacting with
the glucocorticoid receptor (GR). 11β-HSD2 acts as a classical
dehydrogenase by converting active 11-hydroxylated cortisol and
corticosterone (in mice), into inactive 11-keto forms of cortisone
and 11-dehydrocorticosterone, respectively (19, 20). 11β-HSD1,
on the other hand, acts predominantly as an oxidoreductase, con-
verting inactive 11-keto to active 11-hydroxylated corticosteroids
(18, 21, 22). The activities of 11β-HSD enzymes at sites of glu-
cocorticoid action, such as the airway epithelium, are essential
for maintaining the balance between corticosteroid activity and
inactivity, a process termed end-organ metabolism.
Another hallmark feature of asthma is hypersensitivity and
hyperresponsiveness to bronchoconstricting stimuli, including
inhalation of allergens, cold air,or methacholine. Agonists of theβ2
adrenergic receptor (β2-agonists) such as albuterol increase intra-
cellular cAMP, activate protein kinase A, induce transcription of
responsive genes, and trigger relaxation of airway smooth muscle
(23, 24). Consequently, β2-agonists are routinely employed as res-
cue medication for the treatment of acute asthma exacerbations
(i.e., shortness of breath) (24). In addition, β2-agonists may also
be prescribed as a maintenance medication, oftentimes in com-
bination with corticosteroids, to keep airways open and prevent
acute exacerbations.
The short-acting β2-agonist, albuterol, can be synthesized as
two distinct enantiomers: (R)-(levalbuterol) and (S)-albuterol. A
mixture of enantiomers, (R+ S)-albuterol (racemic albuterol) is
less costly to synthesize and is the most commonly used form of
the drug (25). Although it has been debated whether there are
pharmacological advantages to one or the other albuterol enan-
tiomers (26), it is appreciated that levalbuterol is the “active” form
conveying the therapeutic effect of albuterol (27–29), whereas
(S)-albuterol has 100 times less affinity for the β2-receptor and
may generate confounding effects (30, 31) or even function as an
inhibitor for the effects of levalbuterol (32) when present in the
racemic mixture.
Combination therapy with glucocorticoids and β2-agonists
addresses two seemingly distinct hallmarks of the disease. How-
ever, in addition to their bronchodilatory effects, β2-agonists have
anti-inflammatory effects on lung epithelium (33). The combi-
nation of corticosteroids and β2-agonists has been observed to
decrease asthma symptoms, increase overall lung function, and
inhibit inflammatory mediator production by airway epithelial
and other pulmonary cell types better than either medication
alone (34), which suggests that there are synergistic effects of the
combination.
As corticosteroids in combination with β2-agonists generally
provide asthma control (34, 35), yet protracted or systemic corti-
coid use can cause deleterious side-effects (4), the motivation for
our study was to examine whether some of the anti-inflammatory
effects of β2-agonists are mediated through their capacity to
modulate the bioactivity of endogenous corticosteroids in a cell
type and through a signaling pathway relevant to asthma patho-
genesis. It has been demonstrated that the β-agonist, salbutamol,
induces 11β-HSD1 oxidoreductase activity (conversion of inactive
cortisone into active cortisol) in adipocytes (36). We explored in
our studies whether a similar mechanism exists in airway epithelial
cells, which express β-adrenergic receptors (37), and which can be
exploited for therapeutic benefit in the treatment of asthma. Our
long-term goal is to identify pathways that enable efficacious and
affordable asthma control, without the systemic effects of oral
corticosteroids.
MATERIALS AND METHODS
CELL CULTURE AND TREATMENT
Murine bronchiolar epithelial cells (MTCC, SV40 transformed
Club cells) obtained from Dr. Francisco DeMayo (38) were cul-
tured at 37°C in 95% humidified air containing 5% CO2 using
DMEM (Gibco, Grand Island, NY, USA) containing 10% FBS (Cell
Generation, Fort Collins, CO, USA), 2 mM L-glutamine, 50 U/ml
penicillin, and 50µg/ml streptomycin (Gibco). For experimenta-
tion,cells were seeded at 50,000 cells/cm2 and grown to confluence.
Cells were treated with 10−6M (R)-, (S)-, racemic mixture of
(R)- and (S)- albuterol (Sepracor, Marlborough, MA, USA), or
10 ng/ml TNFα (R&D Systems, Minneapolis, MN, USA) for 24 h
after which RNA was isolated. Post-albuterol exposure, cells were
treated with 100 ng/ml lipopolysaccharide (LPS; InvivoGen, San
Diego, CA, USA) or 10 ng/ml TNFα for 16 h after which cell lysates
were prepared for analysis of luciferase (luc) activity and cell-free
conditioned media were collected for measurement of cytokines.
18β-glycyrrhetinic acid, an inhibitor of 11β-HSD, and dexametha-
sone, a synthetic form of cortisol, were purchased from Sigma (St.
Louis, MO, USA).
GENE EXPRESSION
Total RNA was extracted from MTCC cultured on 12-well plates
using the PrepEase RNA isolation kit (USM Corp., Cleveland,
OH, USA) and reverse transcribed to cDNA using the iScript kit
(Bio-Rad, Hercules, CA, USA). Real-time quantitative RT-PCR
was performed using iQ Supermix (Bio-Rad) and intron-spanning
primers on a Bio-Rad Chromo4. Primers were designed for mouse
Hsd11b1 (5′-TTA TTG TCA AGG CGG GAA A5-3′ and 5′-GGC
GTC AAT TAT CCC AGA GA-3′), Hsd11b2 (5′-TCA TCA CCG
GTT GTG ACA CT-3′ and 5′-GGT ATG GCA TGT CTC CTG
CT-3′), and Gapdh (5′-ACG ACC CCT TCA TTG ACC TC-3′
and 5′-TTC ACA CCC ACT ACA AAC AT-3′). The levels of gene
expression were normalized to Gapdh levels and relative expres-
sion was calculated according to the comparative cycle threshold
(∆∆CT) method, as previously described (17).
LUCIFERASE ASSAY
MTCC were stably transfected with a mammalian expression vec-
tor containing an NF-κB-regulated luc reporter (Biomyx Technol-
ogy, San Diego, CA, USA) or a glucocorticoid response element
(GRE; from the mouse mammary tumor virus long terminal
repeat) regulated luc reporter [pHH-luc (39) from Nordeen, Uni-
versity of Colorado Health Sciences Center via Daynes, University
of Utah) using lipofectamine (Life Technologies, Grand Island,
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NY, USA). Stable transfectants were selected using neomycin or
hygromycin (Sigma). For quantitation of luc activity, equal quan-
tities of cellular protein, quantitated by the Bradford method
(Bio-Rad), were extracted following treatment and analyzed using
a Berthold Lumat LB9501 luminometer and luciferin substrate, as
previously described (13).
CYTOKINE MEASUREMENT
Bio-Plex (Bio-Rad, Hercules, CA, USA) kits were designed con-
taining coupled polystyrene beads and antibodies recognizing
mouse IL-1β, IL-6, IL-12p40, IL-12p70, eotaxin, GM-CSF, G-
CSF, KC, MCP-1, MIP-1α, MIP-1β, and RANTES. All assays were
performed in duplicate according to manufacturer’s instructions.
Briefly, 50µl of coupled beads were added to each well of a pre-wet
96-well microtiter plate with filter bottoms, washed twice using a
Bio-Rad (Hercules, CA, USA) Bio-Plex Pro II wash station with
the vacuum plate carrier, and 100µl of sample (cell-free condi-
tioned media), standard, or assay buffer (background) was added
to each well. The plates were covered, shaken vigorously for 1 min
on an IKA (Wilmington, NC, USA) MTS 2/4 digital microtiter
plate shaker and then moderately shaken for 4 h at room tem-
perature. After washing, 25µl of biotinylated detection antibodies
were added to each well for 1 h with shaking followed by addition
of 50µl of streptavidin-PE to all wells for 30 min with shaking.
The wells were washed and the beads were resuspended in 125µl
sheath fluid and shaken to resuspend. Data were acquired at low
PMT setting using the Bio-Rad Bio-Plex suspension array sys-
tem and Bio-Plex Manager 6.0 software. Fluorescence intensity of
the background was subtracted from the values for each sample
and standard for each specific bead. Seven-point standard curves
were generated from fourfold dilutions of standards provided in
the Bio-Plex kits, which were analyzed using five-place logistic
regression from standards within 95–105% of the expected values.
Upper levels of quantitation and lower levels of quantitation were
calculated by the Bio-Plex Manager 6.0 software. Reported concen-
trations are in picograms per milliliter of the cytokines that were
induced by LPS and TNFα and were inhibited by dexamethasone
(IL-6, GM-CSF, G-CSF, KC, MCP-1, MIP-1α, and RANTES).
STATISTICAL CALCULATIONS
Data are presented as mean± SEM and were analyzed by two-way
ANOVA followed by inter-groups analysis by two-tailed unpaired
t -test with Bonferroni correction for multiple comparisons using
GraphPad Prism 6 (San Diego, CA, USA). A p value <0.05 was
considered statistically significant.
RESULTS
R-ALBUTEROL INDUCES 11β-HSD1 GENE EXPRESSION
For our studies, we used a transformed non-ciliated murine airway
epithelial cell line, MTCC (38). These cells, also referred to as Club
cells, represent an abundant cell type lining the conducting airways
of mice and humans, which are amongst those cells anatomically
positioned in vivo such that they are exposed to inhaled bron-
chodilators and steroids (40). Furthermore, we have reported that
murine Club cells are an important regulator of pro-inflammatory
cytokine production through their capacity to activate the tran-
scription factor NF-κB (13–15, 17). For the studies conducted
herein, we first confirmed by Western blot that the MTCC, like
the mouse lung, do indeed express the β2-adrenergic receptor
(data not shown). Although not as abundant on a per micro-
gram protein basis as the whole lung, expression of β2-adrenergic
receptor protein suggested that these cells were well-suited to the
investigation of the effects of albuterol on airway epithelium.
We next investigated whether MTCC express mRNA for 11β-
HSD isoforms, 11β-HSD1, and 11β-HSD2, and whether 11β-HSD
expression was affected by albuterol treatment. We exposed MTCC
to (R)-albuterol, (S)-albuterol, or (R+ S) albuterol at a number
of doses and for a number of durations (data not shown) in order
to establish relevant exposure regimens for our studies. When
MTCC were exposed to 10−6M (R)-albuterol for 24 h there was a
significant increase in the expression of 11β-HSD1 (Figure 1A).
FIGURE 1 | Exposure to (R)-albuterol, but not (S)-albuterol or racemic
(R+S)-albuterol, induces mRNA expression of 11β-HSD1, but not
11β-HSD2, in airway epithelial cells. MTCC were exposed to 10−6M
(R)-albuterol (R), (S)-albuterol (S), racemic (R+S)-albuterol, or 10 ng/ml
TNFα. Twenty-four hours later, RNA was isolated, cDNA was generated, and
11β-HSD1 (Hsd11b1), 11β-HSD2 (Hsd11b2), and GAPDH (Gapdh) gene
expression were analyzed by quantitative PCR. Relative expression of
11β-HSD1 (A) and 11β-HSD2 (B) were calculated. Data were pooled from
three separate experiments. n=6–9/group; *p≤0.05 and **p≤0.01
compared to vehicle.
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However, neither (S)-albuterol nor (R+ S)-albuterol influenced
11β-HSD1 mRNA expression. In addition, none of the albuterol
enantiomers affected the expression of 11β-HSD2 (Figure 1B). As
a positive control, 24 h exposure to 10 ng/ml recombinant mouse
TNFα significantly increased 11β-HSD2 expression. These results
demonstrate that albuterol, in particular (R)-albuterol, selectively
induces 11β-HSD1 expression in airway epithelial cells.
LPS- AND TNFα-INDUCED NF-κB ACTIVITY IS DIMINISHED BY
(R)-ALBUTEROL TREATMENT
Since R-albuterol exposure significantly increased 11β-HSD1
expression in MTCC, we investigated whether albuterol would
diminish NF-κB activity induced by two prototypical agonists, LPS
and TNFα. LPS is an abundant environmental agonist of TLR4,
a receptor important for cellular responses to several asthma-
relevant allergens (41, 42). TNFα is elevated in allergic asthma
and in mouse models of allergic airway disease, wherein it initiates
and amplifies pulmonary inflammatory responses (43). Having
established the half-maximal doses of these agonists, MTCC sta-
bly transfected with a NF-κB-dependent luc reporter gene were
exposed to 100 ng/ml LPS or 10 ng/ml TNFα in the absence
or presence of 10−6M (R)-albuterol, (S)-albuterol, or (R+ S)-
albuterol. While LPS significantly induced NF-κB-luc activity,
simultaneous exposure with albuterol did not diminish LPS-
induced NF-κB activity (data not shown). Similar results were
measured when 10 ng/ml TNFα was substituted for LPS (data
not shown). Although we had hypothesized that simultaneous
treatment with albuterol would diminish LPS- or TNFα-induced
NF-κB activation, we tested whether pretreatment with albuterol
would be more effective. Therefore, MTCC were left untreated
or were treated with 10−6M (R)-, (S)-, or (R+ S)-albuterol for
24 h. Cells were then treated with 100 ng/ml LPS or 10 ng/ml
TNFα for 16 h and analyzed for NF-κB activity. While treat-
ment with LPS (without or with albuterols) significantly increased
NF-κB-dependent luc reporter activity, only pretreatment with
10−6M (R)-albuterol significantly reduced LPS-induced NF-κB
activity (Figure 2A). Similarly, pretreatment with 10−6M (R)-
albuterol also significantly reduced TNFα-induced NF-κB activity
(Figure 2B).
SUPPRESSION OF NF-κB ACTIVITY BY (R)-ALBUTEROL IS DEPENDENT
UPON 11β-HSD1
To elucidate whether the capacity of (R)-albuterol treatment to
diminish NF-κB activity was partially due to the activity of gluco-
corticoids, GRE-dependent luc reporter transfected MTCC were
used. Since we had demonstrated that 24 h pre-exposure of MTCC
to (R)-albuterol augmented 11β-HSD1 expression and dimin-
ished LPS- and TNFα-induced NF-κB activity, GRE-luc MTCC
were either left unexposed or exposed to 10−6M (R)-albuterol
for 24 h. Post-albuterol exposure, 10−6M cortisone (with or with-
out 10−6M of the 11β-HSD inhibitor glycyrrhetinic acid) was
then administered to the cell culture medium and incubated for
an additional 16 h. As a positive control, GRE-luc MTCC were
treated with 10−8M of the synthetic, 11-hydroxy (bioactive) glu-
cocorticoid, dexamethasone for the entire 30 h of the experiment.
Pretreatment with (R)-albuterol followed by exposure to cortisone
modestly but significantly induced GRE-luc activity (Figure 3).
FIGURE 2 | Pre-exposure to (R)-albuterol reduces LPS- and
TNFα-induced NF-κB activity in airway epithelial cells. NF-κB-luciferase
MTCC were exposed to vehicle (veh.) or 10−6M (R)-albuterol (R),
(S)-albuterol (S), or (R+S)-albuterol for 24 h. All cells except control were
then exposed to 100 ng/ml LPS (A) or 10 ng/mlTNFα (B). Sixteen hours later,
cell lysates were prepared, luciferase activity was measured, and protein
concentration was determined. n=5–6/group and the experiment was
repeated twice; **p≤0.01 compared to control, ***p≤0.001 compared to
control, #p≤0.05 compared to vehicle, ##p≤0.01 compared to vehicle.
The effect of (R)-albuterol combined with cortisone was depen-
dent on the activity of 11β-HSD1, as the addition of 10−6M of the
11β-HSD inhibitor glycyrrhetinic acid significantly diminished
GRE-luc activity.
Subsequently, we assessed the role of 11β-HSD1 in albuterol
suppression of NF-κB activity using NF-κB-luc MTCC. Cells
were exposed for 24 h to 10−6M cortisone alone or to 10−6M
(R)-albuterol with or without 10−6M cortisone and 10−6M gly-
cyrrhetinic acid. Following this exposure, cells were stimulated
with 100 ng/ml LPS or 10 ng/ml TNFα for 16 h and NF-κB-
dependent luc activity was measured. As is shown in Figure 4A,
only the combined pretreatment of (R)-albuterol and cortisone
significantly, albeit modestly, decreased LPS-induced NF-κB-luc
activation. Similarly, as is shown in Figure 4B, the combined pre-
treatment with (R)-albuterol and cortisone significantly, albeit
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FIGURE 3 | Pre-exposure of airway epithelial cells to (R)-albuterol for
24 h, followed by cortisone exposure for 16 h, augments GRE-luciferase
activity, which requires the activity of 11β-HSD. GRE-luciferase MTCC
were exposed to 10−8M dexamethasone or 10−6M (R)-albuterol. Twenty-four
hours later, 10−6M cortisone alone or with 10−6M glycyrrhetinic acid was
added for 16 h and luciferase activity and total protein were measured.
n=5–6 samples/group and the experiment was repeated twice;
***p≤0.001 compared to untreated, *p≤0.05 compared to untreated,
#p≤0.05 compared to (R)-albuterol+ cortisone.
modestly, decreased TNFα-induced NF-κB-luc activation. Pre-
treatment with the inactive glucocorticoid, cortisone, had no effect
on LPS- or TNFα-induced NF-κB-luc activity in the absence
of (R)-albuterol. In the cases of both LPS and TNFα exposure,
pretreatment with the 11β-HSD inhibitor, glycyrrhetinic acid,
prevented much of the effect of combined pretreatment with (R)-
albuterol and cortisone, implicating the importance of 11β-HSD1
activity. These experiments demonstrate that only (R)-albuterol
augmented 11-keto corticosteroid induced GRE-luc activation,
indicating that there was a modest but statistically significant con-
version of inactive 11-keto to active 11-hydroxy corticosteroids
capable of inhibiting LPS- and TNFα-induced NF-κB activity.
(R)-ALBUTEROL SUPPRESSES PRODUCTION OF NF-κB-REGULATED
CYTOKINES
We have previously reported the critical contribution that NF-
κB activation in non-ciliated airway epithelial cells (Club cells)
has in mouse models of acute lung injury (44) and allergic air-
way disease (13–17), wherein these cells secrete cytokines that
orchestrate innate and adaptive immune responses. Using MTCC
cells as an in vitro model, we left the cells untreated or pretreated
the cells for 24 h with 10−8M dexamethasone, 10−6M cortisone,
10−6M (R)-albuterol, or a combination of 10−6M (R)-albuterol
and 10−6M cortisone. Cells were then stimulated with 100 ng/ml
LPS or 10 ng/ml TNFα for 16 h and cytokines were measured from
cell-free conditioned medium. As is shown in Figure 5A, only
the combined pretreatment of (R)-albuterol and cortisone sig-
nificantly decreased LPS-induced production of IL-6, GM-CSF,
G-CSF, MCP-1, and MIP-1α. Similarly, the combined pretreat-
ment with (R)-albuterol and cortisone significantly decreased
TNFα-induced production of IL-6, GM-CSF, KC, MCP-1, MIP-1α,
and RANTES (Figure 5B). Notably, pretreatment with cortisone
FIGURE 4 | Pre-exposure of MTCC to (R)-albuterol and cortisone for
24 h, followed by exposure to LPS orTNFα for 16 h, diminishes
NF-κB-luciferase activity, which requires the activity of 11β-HSD.
NF-κB-luciferase MTCC were exposed for 24 h to 10−6M cortisone alone or
to 10−6M (R)-albuterol with or without 10−6M cortisone and 10−6M
glycyrrhetinic acid. Twenty-four hours later, 100 ng/ml LPS (A) or 10 ng/ml
TNFα (B) were added to the cell culture medium. Cells were then lysed 16 h
later using reporter lysis buffer. Luciferase activity and total protein were
then measured. n=4–6 samples/group and the experiment was repeated
twice; ***p≤0.001 compared to untreated, ###p≤0.001 compared to LPS
(A) or TNFα (B), #p≤0.05 compared to LPS (A) or TNFα (B).
alone had no effect on LPS- or TNFα-induced cytokine produc-
tion in the absence of (R)-albuterol. These experiments impli-
cate (R)-albuterol-regulated 11β-HSD1 activity as a potentially
important modulator of pro-inflammatory signaling and cytokine
production in airway epithelial cells.
DISCUSSION
The combination therapy of corticosteroids and β2-agonists has
been typically demonstrated as an effective therapy for many
patients with asthma and COPD. These drugs target airflow
obstruction and airway inflammation, two of the most pressing
features of these pulmonary diseases. β2-adrenergic and GRs are
expressed by many cells within the lung, including airway epithe-
lium, one of the principle cell types exposed when these drugs are
delivered by inhalation. While many of the cell signaling events
activated following β-agonist or glucocorticoid exposure have
been elucidated, there remains a gap in our understanding of how
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FIGURE 5 | Pre-exposure of MTCC to (R)-albuterol and cortisone
diminishes LPS- andTNFα-induced pro-inflammatory cytokine
production. MTCC were exposed to 10−6M (R)-albuterol, with or without
10−6M cortisone or 10−6M glycyrrhetinic acid, or to 10−8M
dexamethasone. Twenty-four hours later, 100 ng/ml LPS (A) or 10 ng/ml
TNFα (B) were added to the cell culture medium. Cell-free conditioned
media were then collected 16 h later and pro-inflammatory cytokine
levels were measured. n=3 samples/group and the experiment was
repeated twice; *p≤0.05, **p≤0.01, ***p≤0.001 compared to LPS
(A) or TNFα (B).
the two drugs may interact synergistically to provide better disease
control than each alone. One possibility is that β2-agonists induce
changes in gene expression that allow for differential sensitivity to
endogenous glucocorticoids. Thereby, higher local concentrations
of bioactive glucocorticoids may be able to provide exceptional
anti-inflammatory activity at the sites in which that activity is
most needed, without the potentially deleterious side-effects that
can be induced by systemic steroids. In support of this hypothesis,
GR function has been reported to increase following β2-agonist
treatment (35).
11β-HSD enzymes interconvert inactive circulating 11-keto
glucocorticoids into bioactive 11-hydroxy steroids capable of
interacting with the GR (45). We have demonstrated that (R)-
albuterol significantly reduces both LPS- and TNFα-induced
NF-κB activity while increasing GRE activation in an 11β-
HSD1 dependent manner, manifesting in lower levels of pro-
inflammatory cytokine production from a transformed mouse
airway epithelial cell line. In this study, we first compared lev-
albuterol to both (S)- and racemic albuterol, wherein we identi-
fied that levalbuterol moderately, but selectively, induces expres-
sion of 11β-HSD1 but not 11β-HSD2, whereas (S)- and racemic
albuterol had no effect on either. The comparison of (R)-, (S)-, and
(R+ S)-albuterol has been studied extensively in clinical or basic
research, with several outcomes supporting the use of (R)- over
(S)-albuterol (28, 46–48). In this vein, there is evidence to suggest
that the (R)-enantiomer is the bioactive component and that the
S-enantiomer may even have detrimental effects (49). Although
others have stated that there is an opposite effect or no difference
between enantiomer treatments (26, 50), one could argue that the
complexity of asthma as a disease could potentiate such differences
in treatment efficacy. It is not clear why in our studies neither the
(S)- nor racemic (R+ S)-albuterol induced 11β-HSD1 expression.
One potential explanation for the lack of response from albuterols
containing the (S)-enantiomer lies in the higher binding affinity of
(R)-albuterol to the β2-adrenergic receptor (32). While our studies
did not enable us to explore this possibility in our airway epithelial
cell model system, the data clearly demonstrate the ability of only
(R)-albuterol to elicit anti-inflammatory effects.
We further addressed whether the anti-inflammatory property
of levalbuterol requires endogenous glucocorticoid signaling. Pre-
vious studies that have attempted to distinguish a route through
which albuterol enhances corticosteroid sensitivity primarily focus
on downstream signaling of the GR following glucocorticoid
exposure and neglect to consider that albuterol may modulate
levels of localized endogenous corticosteroid. A study by Usmani
et al. identified that long-acting β2-agonists could increase nuclear
localization of the GR and increase DNA binding of GR enhanc-
ing glucocorticoid function (51). Our data are complimentary
in this regard for levalbuterol, a short-acting β2-agonist, since
we observed an enhanced GRE-luc activity following levalbuterol
treatment, although only in the presence of cortisone. Conversely,
Eickelberg et al. have suggested that long-acting β2-agonists can
activate the GR independently of corticosteroid binding (52)
whereas Loven et al. suggest a GR independent mechanism (53).
Albeit, we attribute the levalbuterol-mediated GRE-luc activity
observed to GR activation via the conversion of cortisone to cor-
tisol by 11β-HSD1 given that we can inhibit the GRE activity by
the potent 11β-HSD inhibitor,18β-GA. The levalbuterol-mediated
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suppression of NF-κB activity following TNFα or LPS stimula-
tion was also partially prevented following the administration of
18β-GA indicating a role for 11β-HSD1 in the anti-inflammatory
function of levalbuterol. Furthermore, the capacity of 18β-GA to
partially block the inhibitory effects of (R)-albuterol on GRE-
and NF-κB-dependent luc activity specifically implicates neces-
sity for the oxidoreductase (11-keto to 11-hydroxy conversion)
activity of 11β-HSD1 for albuterol-mediated suppression of NF-
κB. By extension, the requirement for (R)-albuterol pretreatment
and the addition of cortisone for the diminution of LPS- and
TNFα-induced pro-inflammatory cytokine production implies
that active glucocorticoids mediate this effect.
Whether the effects of (R)-albuterol observed in vitro would
translate into biologically significant reductions in inflammatory
cytokine or chemokine production in vivo remain unknown. In
addition, it is uncertain whether airway epithelium is the most
relevant cell type in which to study 11β-HSD activities in response
to β2-agonists. While the MTCC cell line was utilized for our
studies based on the important functions we have attributed to
NF-κB activity in Club cells of mice (13–17, 44), MTCC retain
only a limited number of the characteristics of in vivo Club cells
(38) and are not representative of the more abundant ciliated
airway epithelial cells lining the conducting airways of humans.
Furthermore, our cell model system did not involve culturing at
an air-liquid interface, which is more representative of the in vivo
state of differentiated airway epithelium. Our studies should be
extended to primary cells from healthy mice and those with allergic
airway disease, as well as to healthy human subjects and those
with different asthma endotypes (54). In addition to epithelia,
many other types of cells present in the inflamed airway, includ-
ing lymphocytes and macrophages that are pathogenic in asthma
and COPD, express 11β-HSD1 (55, 56) and may be modulated
in their activity by β2-agonists (57, 58). Nevertheless, the modest
reductions we observed in vitro are of a similar magnitude to what
has been recently reported from an elegant in vivo study using
a mouse model of allergic asthma in which (R)-albuterol mod-
estly diminished inflammation and NF-κB activity (58). Finally,
whether the observed effects of (R)-albuterol would also be mim-
icked or even enhanced by a long-acting β2-agonists, such as
(R,R)-formoterol, which do diminish inflammatory cytokine pro-
duction by human airway epithelial cells in vitro (59), remains
an intriguing question. Certainly, there is the potential that long-
term augmentation of airway epithelial 11β-HSD1 oxidoreductase
activity could provide endogenous glucocorticoids with powerful
and localized anti-inflammatory activities. Our finding that pre-
treatment of epithelial cells with (R)-albuterol was required to
elicit inhibitory effects on LPS- or TNFα-induced activation sug-
gests that maintenance therapy [with (R)-albuterol] may be more
beneficial than as-needed treatment.
Taken together, our results define a mechanism by which lev-
albuterol may suppress airway inflammation (Figure 6). Trans-
lation of our in vitro findings suggests that β2-agonist induced
enhancement of 11β-HSD1 oxidoreductase activity in the air-
way epithelium of asthmatic patients has the potential to increase
FIGURE 6 | Proposed mechanism of action. By signaling through the
β2-adrenergic receptor, (R)-albuterol transcriptionally upregulates the mRNA
expression and oxidoreductase activity of 11β-HSD1 in airway epithelial cells,
thereby potentiating the anti-inflammatory effects of endogenous
glucocorticoids to inhibit activity of the pro-inflammatory transcription factor
NF-κB.
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the metabolic activation of their endogenous cortisol and sup-
press baseline inflammatory responses, in particular those involv-
ing transcriptional control by NF-κB. Through the activation
of endogenous corticosteroids selectively in the affected lung
epithelium, levalbuterol and potentially other β2-agonists could
be used as a tool enabling clinicians to circumvent the use of
long-term or systemic corticosteroid therapies for the treatment
of inflammatory airway diseases.
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